Karin Storm Van's Gravesande1, Astrid Blaschek2, Pasquale Calabrese3, Kevin Rostásy4, Peter Huppke5, Josef Kessler J6, Elke Kalbe7, Volker Mall8. 1. Department of Pediatrics, Child and Adolescent Psychosomatics, Technische Universität München, Heigelhofstr. 63, 81377 Munich, Germany. Electronic address: karin.storm@gmx.de. 2. Department of Pediatric Neurology and Developmental Medicine, Dr. von Hauner Children's Hospital, Ludwig-Maximilians-University, Lindwurmstrasse 4, 80337 Munich, Germany. 3. Neuropsychology and Behavioral Neurology Unit, Division of Molecular and Cognitive Neuroscience, Department of Psychology, University of Basel, Birmannsgasse 8, 4055 Basel, Switzerland. 4. Pediatric Neurology, Witten/Herdecke University, Children's Hospital Datteln, Dr. Friedrich Steiner Str. 5, 5711 Datteln, Germany. 5. Department of Pediatrics and Adolescent Medicine, Division of Pediatric Neurology, University Medical Center Göttingen, Robert-Koch Strasse 40, 37075 Göttingen, Germany. 6. Department of Neurology, University Hospital Cologne, Kerpenerstr. 62, 50937 Cologne, Germany. 7. Department of Medical Psychology ǀ Neuropsychology and Gender Studies & Center for Neuropsychological Diagnostics and Intervention (CeNDI), University Hospital Cologne, Kerpenerstr. 62, 50937 Cologne, Germany. 8. Department of Pediatrics, Child and Adolescent Psychosomatics, Technische Universität München, Heigelhofstr. 63, 81377 Munich, Germany.
Abstract
BACKGROUND: Fatigue, depression and loss in health-related quality of life (HRQoL) have been reported to occur in a substantial amount of patients with pediatric-onset MS (POMS). This study aims to evaluate depression, fatigue and HRQoL and its relationship in a cohort of patients with POMS and matched healthy controls (HCs). METHODS: In a multicenter cross-sectional study, Beck Depression Inventory II, Depressionstest für Kinder, the Pediatric Quality of Life Inventory (PedsQL™) 4.0 Generic Core Scale and the PedsQL™ Multidimensional Fatique Scale were performed. RESULTS: In a cohort of 106 patients with POMS and 210 matched HCs, patients were significantly more often depressed (21.7% vs. 11.4%, p = 0.014) experienced greater fatigue (40.6% vs. 17.3%, p < 0.001) and a greater loss of HRQoL (43.4% vs. 15%, p < 0.001) than controls. Depression predicted 51.8% of variance of fatigue. Fatigue was also predicted by female gender. Loss of HRQoL was predicted by EDSS, depression and fatigue. Depression and fatigue together explained 67.7% of variance of HRQoL. CONCLUSION: Patients with POMS are at a significant increased risk for depression, fatigue and loss of HRQoL. Furthermore, fatigue and depression significantly predict reduced HRQoL in POMS, suggesting that testing for these symptoms and early therapy is of utmost importance in all patients with POMS.
BACKGROUND:Fatigue, depression and loss in health-related quality of life (HRQoL) have been reported to occur in a substantial amount of patients with pediatric-onset MS (POMS). This study aims to evaluate depression, fatigue and HRQoL and its relationship in a cohort of patients with POMS and matched healthy controls (HCs). METHODS: In a multicenter cross-sectional study, Beck Depression Inventory II, Depressionstest für Kinder, the Pediatric Quality of Life Inventory (PedsQL™) 4.0 Generic Core Scale and the PedsQL™ Multidimensional Fatique Scale were performed. RESULTS: In a cohort of 106 patients with POMS and 210 matched HCs, patients were significantly more often depressed (21.7% vs. 11.4%, p = 0.014) experienced greater fatigue (40.6% vs. 17.3%, p < 0.001) and a greater loss of HRQoL (43.4% vs. 15%, p < 0.001) than controls. Depression predicted 51.8% of variance of fatigue. Fatigue was also predicted by female gender. Loss of HRQoL was predicted by EDSS, depression and fatigue. Depression and fatigue together explained 67.7% of variance of HRQoL. CONCLUSION:Patients with POMS are at a significant increased risk for depression, fatigue and loss of HRQoL. Furthermore, fatigue and depression significantly predict reduced HRQoL in POMS, suggesting that testing for these symptoms and early therapy is of utmost importance in all patients with POMS.
Authors: Matthew F Smout; Gian Mauro Manzoni; Sofia Tamini; Nicoletta Marazzi; Alessandra De Col; Giada Pietrabissa; Gianluca Castelnuovo; Enrico Molinari; Alessandro Sartorio Journal: Health Qual Life Outcomes Date: 2022-01-10 Impact factor: 3.186
Authors: Jennifer S Graves; Marius Thomas; Jun Li; Anuja R Shah; Alexandra Goodyear; Markus R Lange; Heinz Schmidli; Dieter A Häring; Tim Friede; Jutta Gärtner Journal: Ther Adv Neurol Disord Date: 2022-05-01 Impact factor: 6.430
Authors: Laura Rosa; Maria Petracca; Antonio Carotenuto; Pasquale Dolce; Kyrie Piscopo; Francesca Dicé; Francesca Lauro; Antonio Luca Spiezia; Marcello Moccia; Luigi Lavorgna; Carmine Iacovazzo; Giuseppe Servillo; Nelson Mauro Maldonato; Alessandro Chiodi; Vincenzo Brescia Morra; Roberta Lanzillo Journal: J Clin Med Date: 2022-09-04 Impact factor: 4.964